Protalex, Inc. (PRTX) Adds Three Industry Leaders To Clinical Development Team
5/5/2014 6:55:17 AM
Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, announces the engagement of three senior industry leaders to advance the clinical development of the Company’s lead product candidate PRTX-100, a formulation of a proprietary, highly purified form of Staphylococcal Protein A. Joining Protalex’s leadership team are John B.L. McClain, M.D. as Medical Director, Richard J. Francovitch, Ph.D. as Vice President of ITP Programs, and Michelle Catalina, Ph.D. as Director of Preclinical Studies. Each will also join the Company’s Scientific Advisory Board (SAB).
Help employers find you! Check out all the jobs and post your resume.
comments powered by